Welcome to our dedicated page for Axogen news (Ticker: AXGN), a resource for investors and traders seeking the latest updates and insights on Axogen stock.
Axogen, Inc. develops and commercializes surgical solutions for peripheral nerve regeneration and repair. The company’s recurring updates center on its portfolio for restoration of peripheral nerve function, including Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™.
Company news also includes quarterly and annual financial results, revenue guidance, gross margin and cash metrics, investor-conference participation, FDA-related developments for Avance, and capital-structure actions involving common stock. These updates connect operating performance with Axogen’s commercial activity in nerve repair products across its target markets.
Axogen (NASDAQ: AXGN) announced that Karen Zaderej, chairman, CEO, and president, will present at the Cantor Virtual Global Healthcare Conference on September 16, 2020, at 1:20 p.m. ET. The presentation will be available via live webcast on the company's Investors page.
Axogen is a leader in developing surgical solutions for peripheral nerve damage, offering products like Avance® Nerve Graft and Axoguard® Nerve Protector to enhance recovery and improve patients' quality of life.
Axogen, a leader in surgical solutions for peripheral nerve repair, announced that CEO Karen Zaderej will present at the Canaccord Genuity 40th Annual Growth Conference on August 12, 2020, at 9:00 a.m. ET. The presentation will be available via live webcast on Axogen's investor page, with a replay accessible for 90 days. Axogen specializes in innovative technologies for nerve regeneration, offering a range of products including Avance Nerve Graft and Axoguard products to assist in nerve repair and protection. The company is committed to improving patient outcomes in nerve function restoration.
Axogen, Inc. (NASDAQ: AXGN) will release its second quarter 2020 financial results on August 5, 2020, post-market. The company's management will hold a conference call and webcast at 4:30 p.m. ET to discuss these results. Axogen is recognized for its innovative surgical solutions for peripheral nerve damage, including its portfolio of products like Avance® Nerve Graft and Axoguard® series. Investors can join the call by phone or through the company's website. A replay will be available after the call.
Axogen, Inc. (NASDAQ: AXGN) announced a financing agreement with Oberland Capital, allowing for up to $75 million in tranches. The first tranche of $35 million was drawn on June 30, 2020. Preliminary revenue for Q2 2020 is estimated at $21 million, down 21% from the previous year. The financing will support expansion, including a new biologic processing center. The CEO noted a regional recovery in nerve repair procedures but cautioned that COVID-19 continues to impact surgical volume, leading to a cautious revenue outlook for the remainder of the year.
Axogen, a leader in innovative surgical solutions for peripheral nerve repair, announced Brad Ottinger as the new General Counsel and Chief Compliance Officer effective June 1, 2020. Ottinger brings over 25 years of experience in legal and compliance roles within the medical device sector, previously serving at MicroPort Orthopedics. He succeeds Greg Freitag, who retired but will remain on the Board of Directors as Special Counsel. CEO Karen Zaderej expressed confidence in Ottinger's expertise, highlighting its importance for the company's growth and compliance efforts in the nerve repair market.
Axogen, Inc. (NASDAQ: AXGN) announced that Karen Zaderej, CEO and chairman, will present at the Jefferies Virtual Healthcare Conference on June 3, 2020, at 2:00 p.m. ET. The presentation will be available via a live webcast on the company’s Investors page and can be replayed for 90 days after the event. Axogen focuses on innovative surgical solutions for peripheral nerve damage, with a portfolio that includes products like Avance® Nerve Graft and Axoguard® Nerve Protector, aimed at restoring nerve function and improving patient quality of life.
Axogen, Inc. (NASDAQ: AXGN) reported Q1 2020 net revenue of $24.3 million, a 4% increase from Q1 2019. However, gross margin declined to 80.1%. The company posted a net loss of $8.2 million or $0.21 per share, compared to a loss of $9.5 million in the same quarter last year. Active accounts rose by 13% to 825. Due to COVID-19, the company suspended its 2020 guidance, foreseeing reduced revenues. Additionally, Axogen returned a $7.8 million PPP loan amid changing eligibility standards. A class action lawsuit was dismissed, and cost-cutting measures were implemented.